MorphoSys AG
FRANKFURT : MOR

May 20, 2011 01:37 ET

MorphoSys Announces Re-election of Two Supervisory Board Members

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - May 20, 2011) -


MorphoSys AG /

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at the Company's annual shareholder meeting on Thursday, May 19, 2011, its shareholders confirmed the reappointment of Prof. Dr. Jürgen Drews and Dr. Walter Blättler as members of the Company's Supervisory Board.

"We are pleased to announce the re-election of two experienced members of the Supervisory board and look forward to continue working with them," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Their enormous contributions, especially in the areas of technology and product development, have been critical to MorphoSys's success."

The shareholders of MorphoSys AG approved all management proposals put to vote at the meeting including:

-- Granting full discharge to the members of the Management Board and the Supervisory Board for their activities during the business year 2010

-- The appointment of PricewaterhouseCoopers AG as auditors of the Company and the MorphoSys Group for the business year 2011

-- The repurchase of treasury stock up to a total of 10 % of the share capital until April 30, 2016

-- The creation of a new conditional capital 2011-I to issue option and/or convertible bonds

-- The amendment of compensation of the Supervisory Board by secondary payments

At the Annual General Meeting of MorphoSys AG 30.5% of the voting shares were represented.


About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.


This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


--- End of Message ---

MorphoSys AG

Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;


Press Release (PDF): http://hugin.info/130295/R/1517458/454011.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1517458]

Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact